Cannus

Cannus is a South Korea-based biotechnology company specializing in the development of first-in-class therapeutics for neurodegenerative disorders and cancer. The company's primary focus is on restoring protein homeostasis, particularly through the modulation of progranulin (PGRN) levels and the clearance of misfolded proteins like TDP-43 and alpha-synuclein. Their pipeline includes small molecule candidates targeting Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS). By utilizing proprietary screening platforms, Cannus aims to deliver disease-modifying treatments that address the underlying mechanisms of CNS degeneration. The company is currently advancing its lead programs through preclinical development toward clinical-stage evaluation.